Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | BLM | P54132 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metahexamide SCHEMBL30107709 | 1.00 | ADORA3 (0.68) | ADORA3ALDH1A1LMNATSHRBLM | |
| Metahexamide SCHEMBL15845574 | 0.85 | ADORA3 (0.62) | ADORA3ALDH1A1LMNATSHRBLM | |
| Gliclazide SCHEMBL13723694 | 0.85 | ALDH1A1 (0.67) | ADORA3ALDH1A1LMNATSHRBLM | |
| SCHEMBL23736042 | 0.81 | ADORA3 (0.74) | ADORA3ALDH1A1LMNATSHRBLM | |
| Glycyclamide SCHEMBL49386 | 0.81 | ADORA3 (1.00) | ADORA3ALDH1A1LMNATSHRBLM | |
| Heptolamide SCHEMBL1814750 | 0.81 | ADORA3 (1.00) | ADORA3ALDH1A1LMNATSHRBLM | |
| Glyoctamide SCHEMBL667731 | 0.81 | ADORA3 (1.00) | ADORA3ALDH1A1LMNATSHRBLM | |
| Glycyclamide SCHEMBL21722119 | 0.80 | ADORA3 (0.97) | ADORA3ALDH1A1LMNATSHRBLM | |
| Hydrochloric Acid SCHEMBL9796358 | 0.80 | ALDH1A1 (0.71) | ALDH1A1LMNATSHRTDP1GAA | |
| Tolpentamide SCHEMBL2109411 | 0.80 | ADORA3 (0.97) | ADORA3ALDH1A1LMNATSHRBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 904 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232448-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | Halo Therapeutics Ltd (GB) | 2023-08-30 | — | — | EP | claimed |
| US-20220184070-A1 | LOW-DOSE TRIPLE COMBINATION FORMULATION | The George Institute for Global Health (AU) | 2022-06-16 | — | — | US | claimed |
| WO-2022083853-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | GBIOTECH S.À.R.L. (CH) | 2022-04-28 | — | — | WO | claimed |
| EP-3946343-A1 | LOW-DOSE TRIPLE COMBINATION FORMULATION | The George Institute For Global Health (AU) | 2022-02-09 | — | — | EP | claimed |
| US-11213508-B2 | Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion | UNIVERSITE DE MONTPELLIER (FR) | 2022-01-04 | — | — | US | claimed |
| EP-3833336-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DalCor Pharma UK Ltd Leatherhead, Zug Branch (CH) | 2021-06-16 | — | — | EP | claimed |
| EP-2459227-B1 | Prodrugs containing an aromatic amine connected by an amide bond to a carrier | ASCENDIS PHARMA AS (DK) | 2021-03-17 | — | — | EP | claimed |
| WO-2020194046-A1 | LOW-DOSE TRIPLE COMBINATION FORMULATION | The George Institute for Global Health (AU) | 2020-10-01 | — | — | WO | claimed |
| CN-111201022-A | Use of gaboxadol for treating diabetes and related conditions | 奥维德医疗公司 | 2020-05-26 | — | — | CN | claimed |
| US-20200155504-A1 | COMPOSITIONS COMPRISING UROLITHINS AND USES THEREOF FOR THE STIMULATION OF INSULIN SECRETION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2020-05-21 | — | — | US | claimed |
| CN-1250226-C | Combination comprising -2-ethoxy-3- [4- (2- { 4-methanesulfonyloxyphenyl } ethoxy) phenyl ] propanoic acid or 3- {4- [2- (4-tert-butoxycarbonylaminophenyl) ethoxy ] phenyl } - -2-ethoxypropanoic acid and a sulfonylurea | ASTRAZENECA AB (SE) | 2006-04-12 | — | — | CN | claimed |
| CN-1212117-C | Pharmaceutical composition for treating diabetes | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-07-27 | — | — | CN | claimed |
| CN-1599612-A | Combination of FBP enzyme inhibitor and antidiabetic agent for treating diabetes | METABASIS THERAPEUTICS INC (US) | 2005-03-23 | — | — | CN | claimed |
| CN-1537008-A | Combination comprising -2-ethoxy-3- [ 4- (2- { 4-methanesulfonyloxyphenyl } ethoxy) phenyl ] propanoic acid or 3- { 4- [ 2- (4-tert-butoxycarbonylaminophenyl) ethoxy ] phenyl } - -2-ethoxypropanoic acid and a sulfonylurea | — | 2004-10-13 | — | — | CN | claimed |
| US-20040068005-A1 | Pharmaceutical combinations | KERI PHARMA GENERICS KFT. (HU) | 2004-04-08 | — | — | US | claimed |
| EP-1303304-A2 | PHARMACEUTICAL COMBINATIONS FOR TREATMENT AND PREVENTION OF DIABETES MELLITUS | Keri Pharma KFT (HU) | 2003-04-23 | — | — | EP | claimed |
| CN-1400908-A | Combinations comprising dipeptidyl peptidase-IV inhibitors | NOVARTIS AG (CH) | 2003-03-05 | — | — | CN | claimed |
| WO-2002005795-A2 | PHARMACEUTICAL COMBINATIONS FOR TREATMENT AND PREVENTION OF DIABETES MELLITUS | Kéri Pharma Kft. (HU) | 2002-01-24 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| CN-1264303-A | Treatment of diabetes with thiazolidinediones, insulin secretagogues and biguanides | SMITHKLINE BEECHAM PLC (GB) | 2000-08-23 | — | — | CN | claimed |